This biopharma play with two key drugs for treatment-resistant depression could see its stock rise by more than 230%, according to a Deutsche Bank analyst.
Get this delivered to your inbox, and more info about our products and services.
Some psychedelic stocks can rally after the executive order on the use of the this type of drug for mental health, Oppenheimer…
Regeneron's deep pipeline of potentially successful drugs helps to offset competitive risks in other areas.
The bank initiated the clinical-stage biotechnology firm at a buy rating.
BofA analysts are bullish on this German medtech name ahead of its full-year earnings report.
Goldman Sachs sees shares of Biohaven rallying 114% after plunging 72% over the past 12 months.
The investment bank upgraded the pharma stock to overweight from equal weight.
